

Applicant: Jerzy A. Georgiades  
Serial No. 09/719,944  
Filing Date: 02-MAY-01  
Group Art Unit: 1646  
Page 4

such that the trademarks SMA<sup>TM</sup> and WHITE<sup>TM</sup> are now capitalized. No new matter has been added to the application.

### ***Claim Rejections - 35 U.S.C. §112***

Also in the prior Office Action, the Examiner rejected claims 3 and 4 under 35 U.S.C. §112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the applicant regards as the invention. Specifically, the Examiner noted that there was insufficient antecedent basis for the limitation in claim 3 that begins "the selenium". By this Amendment, claim 3 has been amended to depend from claim 2, rather than claim 1. There is clearly now sufficient antecedent basis for the limitation in claim 3 that begins "the selenium".  
Reconsideration of the rejection of claim 3 is respectfully requested.

The Examiner rejected claim 4 as being indefinite and ambiguous for recitation of "tissue necrosis factor". Applicant notes that "tissue necrosis factor  $\alpha$ " is actually recited in claim 4. Tissue necrosis factor  $\alpha$  is a well-known member of the interferon family, as is noted on page 5, lines 4-8 of the specification. Thus, recitation of "tissue necrosis factor  $\alpha$ " in claim 4 is not indefinite, novel, or confusing, and would readily be understood by one of ordinary skill in the art. In light of the foregoing clarification, reconsideration of the rejection of claim 4 is respectfully requested.

Applicant: Jerzy A. Georgiades  
Serial No. 09/719,944  
Filing Date: 02-MAY-01  
Group Art Unit: 1646  
Page 5

***Claim Rejections - 35 U.S.C. §102***

In the prior Office Action, the Examiner rejected claim 1 under 35 U.S.C. §102(b) as being anticipated by Cockrum, GB 2,289,278 (Immuno-Dynamics Inc.). The Cockrum, GB 2,289,278 (Immuno-Dynamics Inc.) reference describes a dietary supplement that includes dried colostral powder.

By this Amendment, applicant has amended claim 1 to specify that the dietary supplement comprises *purified* colostrinin. This amendment to claim 1 clearly adds no new matter to the application (support for the amendment to claim 1 can be found on page 4, line 19).

Applicant submits that the amendment to claim 1 clearly differentiates the dietary supplement as claimed in claim 1 in the present application from the dietary supplement disclosed in the Cockrum, GB 2,298,278 (Immuno-Dynamics Inc.) reference. The Cockrum, GB 2,298,278 (Immuno-Dynamics Inc.) reference clearly does not disclose, teach or suggest a dietary supplement comprising *purified* colostrinin as claimed. Dried colostral powder, while containing some colostrinin, is not the same as *purified* colostrinin, as claimed.

Applicant notes that the Cockrum, GB 2,298,278 (Immuno-Dynamics Inc.) reference was cited and considered during prosecution of application from which the present application claims priority, namely Georgiades, GB 2,354,153 (ReGen Biotech Limited). Claim 1 of the present application, as amended, is now identical to claim 1 of

Applicant: Jerzy A. Georgiades  
Serial No. 09/719,944  
Filing Date: 02-MAY-01  
Group Art Unit: 1646  
Page 6

the priority application, which was allowed over the Cockrum, GB 2,298,278 (Immuno-Dynamics Inc.) reference (see copies of GB 2,354,153 bibliography and Status Information attached hereto). Reconsideration of the rejection of claim 1 is respectfully requested.

***Claim Rejections - 35 U.S.C. §103***

The Examiner rejected claims 2-4 under 35 U.S.C. §103(a) as being unpatentable over Cockrum, GB 2,298,278 (Immuno-Dynamics Inc.) as applied to claim 1 further in view of Janusz et al., WO 98/14473, Adler et al., WO 97/43905, Hiroto et al., JP 2,265,458 (Nikken Food KK), and Inglot et al., 1996 Arch. Immunologiae et Therapiae Experimentalis, Vol. 44, pp. 215-224. Applicant notes that only Janusz et al., WO 98/14473, discloses purified colostrinin, but this reference does not disclose, teach or suggest a dietary supplement comprising purified colostrinin in combination with lactoferrin and/or selenium. There is no teaching in Janusz et al., WO 98/14473, nor in the other cited references, whereby one of skill in the art would be motivated to create a dietary supplement comprising purified colostrin in combination with lactoferrin and/or selenium. Accordingly, the rejection of claims 2-4 under 35 U.S.C. §103(a) is clearly improper. Reconsideration of the rejection is respectfully requested.

Claims 7 and 8 were rejected under 35 U.S.C. §103(a) as being unpatentable over Cockrum, GB 2,298,278 (Immuno-Dynamics Inc.) as applied to claim 1 further in view of Plaut et al., WO 97/05884 (New England Medical Center Hospital) and Adler et

Applicant: Jerzy A. Georgiades  
Serial No. 09/719,944  
Filing Date: 02-MAY-01  
Group Art Unit: 1646  
Page 7


al., WO 97/43905. None of the references cited against claims 7 and 8 discloses, teaches or suggests a baby food formulay comprising a dietary supplement comprising *purified* colostrinin in combination with lactoferrin. The rejection of claims 7 and 8 is therefore improper. Reconsideration of the rejection is respectfully requested.

### CONCLUSION

In light of the foregoing, it is submitted that the application is presently in condition for allowance, and a notice to that effect is therefore earnestly solicited.

Respectfully submitted,

RANKIN, HILL, PORTER & CLARK LLP



---

Stephen A. Hill  
Reg. No. 27,560  
Randolph E. Digges, III  
Reg. No. 40,590

925 Euclid Avenue  
Suite 700  
Cleveland, Ohio 44115-1405  
(216) 566-9700

**ATTACHMENT A**  
**(Version Showing Changes Made)**

***In the Specification:***

The paragraph beginning on page 8, line 3, was amended as follows:

A formulation for feeding to a baby post weaning from mother's milk, is:

Proprietary milk powder

(e.g. [~~Sma<sup>TM</sup>~~, ~~White<sup>TM</sup>~~] SMA<sup>TM</sup>, WHITE<sup>TM</sup> by Sma

Nutrition, Maidenhead, U.K. \*) 4g \*\*

Natural ovine colostrinin 150µg

Selenium (bound to

lactobacilius acidophilus) 8.25µg (free selenium)

Human Recombinant Lactoferrin 1.0 mg

- \* [~~Sma<sup>TM</sup>~~] SMA<sup>TM</sup> ingredients quoted as lactose, skimmed milk powder, vegetable oils, emulsifier (soy lecithin), potassium bicarbonate, vitamin C, taurine, ferrous sulfate, zinc sulfate, cytidine-5'-monophosphate, disodium uridine-5'-monophosphate, vitamin E adenosin-5'-monophosphate, niacin, disodium inosine-5'-monophosphate, disodium guanosine-5'-

monophosphate, pantothenic acid, vitamin A, copper sulphate, thiamin, vitamin B, riboflavin, beta-carotene, manganese sulphate, folic acid, vitamin K, potassium iodide, biotin, vitamin D, vitamin B. Although the manufacturer lists ferrous sulphate as an ingredient, we prefer not to include this material or any other iron containing compounds.

- \*\* Follow manufacturer's instructions for dosage guide e.g. weight 6.5 kg, approximate age of baby 4 months, 7 level scoops in 200 ml cooled (freshly boiled) water.

***In the Claims:***

Claims 1 and 3 were amended to read as follows:

1. (AMENDED) A dietary supplement comprising purified colostrinin in combination with lactoferrin.
3. (AMENDED) A dietary supplement according to claim [4] 2, wherein the selenium is in the form of a physiologically acceptable selenoprotein.

(12) **UK Patent Application** (19) **GB** (11) **2 354 153** (13) **A**

(43) Date of Printing by UK Office 21.03.2001

(21) Application No 0101051.1

(22) Date of Filing 15.06.1999

(30) Priority Data

(31) 9813031 (32) 16.06.1998 (33) GB

(86) International Application Data

PCT/GB99/01878 En 15.06.1999

(87) International Publication Data

WO99/65329 En 23.12.1999

(51) INT CL<sup>7</sup>

A23C 9/20 , A23L 1/305 , A61K 35/20

(52) UK CL (Edition S )

A2B BMDE1 BMDE9 B852 B867

(56) Documents Cited by ISA

GB 2289278 A WO 98/14473 A WO 97/43905 A  
WO 97/05884 A

(58) Field of Search by ISA

INT CL<sup>7</sup> A23C , A23L , A61K

(71) Applicant(s)

ReGen Biotech Limited  
(Incorporated in the United Kingdom)  
8 Baker Street, LONDON, W1M 1DA, United Kingdom

(74) Agent and/or Address for Service

A.A.Thornton & Co  
235 High Holborn, LONDON, WC1V 7LE,  
United Kingdom

(72) Inventor(s)

Jerzy A Georgiades

(54) Abstract Title

Dietary supplement

(57) A dietary supplement comprises a combination of colostrinin and at least one of lactoferrin and selenium.

GB 2 354 153 A

10/10/17

CLAIMS

1. A dietary supplement comprising purified colostrinin in combination with lactoferrin.
2. A dietary supplement according to claim 1, further comprising selenium.
3. A dietary supplement according to claim 1, wherein the selenium is in the form of a physiologically acceptable selenoprotein.
4. A dietary supplement according to claim 1, further comprising at least one cytokine selected from interferon  $\alpha$ , interferon  $\gamma$ , interleukin 1- $\alpha$ , interleukin 1-3, interleukin 6, 8, 10, 12, 16, tissue necrosis factor  $\alpha$ , G-CSF, M-CSF, TGF $\alpha$  and TGF $\beta$ .
5. A dietary supplement comprising purified colostrinin in combination with selenium.
6. A dietary supplement comprising colostrinin in combination with at least one cytokine selected from interferon  $\alpha$ , interferon  $\gamma$ , interleukin 1- $\alpha$ , interleukin 1-3, interleukin 6, 8, 10, 12, 16, tissue necrosis factor  $\alpha$ , G-CSF, M-CSF, TGF $\alpha$  and TGF $\beta$ .
7. A baby food formula comprising a dietary supplement according to any preceding claim.
8. The use of dietary supplement according to any preceding claim in a baby food formula.
9. A tablet lozenge or other solid oral dosage form comprising 12.5 micrograms to 200 micrograms purified colostrinin, 10 micrograms to 100 milligrams lactoferrin, and 2.5 to 100 micrograms seleno-cysteine in combination with a physiologically acceptable carrier.



10. The use of purified colostrinin in combination with lactoferin in the manufacture of a medicament for improving the immune system of mammals.

11. The use of purified colostrinin in combination with selenium in the manufacture of a medicament for improving the immune system of mammals.

12. The use of purified colostrinin in combination with at least one cytokine selected from interferon  $\alpha$ , interferon  $\gamma$ , interleukin 1- $\alpha$ , interleukin 1-3, interleukin 6, 8, 10, 12, 16, tissue necrosis factor  $\alpha$ , G-CSF, M-CSF, TGF $\alpha$  and TGF $\beta$  in the manufacture of a medicament for improving the immune system of mammals.



Copyright  
Designs  
Trade Marks

# Patents

Contact Details

Search

Site Map

Index

Home : [Patents](#) : [Database](#) : [Status](#)

## PATENTS STATUS INFORMATION FULL DETAILS

Please click on button below to view the published patent application via esp@cenet.

[ESP@CENET](#)

REGISTER ENTRY FOR GB2354153

Form NP1 Application No GB0101051.1 filing date 15.06.1999

Lodged on 15.01.2001

Priority claimed:

16.06.1998 in United Kingdom - doc: 9813031

PCT NATIONAL PHASE

PCT Application PCT/GB1999/001878 filed on 15.06.1999 in English

Publication No WO1999/065329 on 23.12.1999 in English

Title DIETARY SUPPLEMENT

Applicant/Proprietor

REGEN BIOTECH LIMITED, Incorporated in the United Kingdom, 8 Baker Street,  
LONDON, W1M 1DA, United Kingdom [ADP No. 07448491003]

Inventor

JERZY A GEORGIADES, 9615 Bayou Brook, Houston, Texas 77063, United States  
of America [ADP No. 07672165001]

Classified to

A2B

A23C A23L A61K

Address for Service

A A THORNTON & CO, 235 High Holborn, LONDON, WC1V 7LE, United Kingdom  
[ADP No. 00000075001]

Publication No GB2354153 dated 21.03.2001

Examination requested 15.01.2001

Grant of Patent (Notification under Section 18(4)) 17.09.2002

Publication of notice in the Patents and Designs Journal (Section 25(1))

16.10.2002

Title of Granted Patent DIETARY SUPPLEMENT

\*\*\*\* END OF REGISTER ENTRY \*\*\*\*

---

RENEWALS DATA

Date Filed	15.06.1999
Date Not in Force	
Date of Last Renewal	
Year of Last Renewal	
Date Next Renewal Due	15.06.2003
Status	PATENT IN FORCE

ESP@CENET

---

[New Enquiry](#)

